Compare Heron Therapeutics Inc (HRTX) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs McCormick & Company, Incorporated — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while McCormick & Company, Incorporated trades at $44.81 (market cap $12.39B). The key difference: McCormick & Company, Incorporated is far larger — about 182.2× Heron Therapeutics Inc's market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and McCormick & Company, Incorporated for 67 Days on average.
| HRTX | MKC | |
|---|---|---|
Market Cap | $68.01M | $12.39B |
Volume | 1,891,941 | 6,140,872 |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $71.65 |
52-Week Low | $0.27 | $44.14 |
Typical Hold Time | 35 Days | 67 Days |
Enterprise Value | $174.75M | $17.07B |
Dividend Yield | — | 4.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
MKC trades at $45.005, down 0.54% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q3 2026 results with 17% sales growth and margin expansion, supported by the McCormick de Mexico acquisition. Valuation metrics appear attractive with a P/E of 8.31 and net income margin of 19.39%, while analyst consensus shows a mixed but predominantly hold rating.
The stock presents value opportunities with below-sector P/E ratios and consistent dividend payments, but faces technical headwinds and competitive pressures. Upside potential exists toward the $53.50 consensus target, though investors should monitor integration execution and consumer spending trends given the bearish technical indicators and mixed analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
